
## Shirish Gadgeel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/114995/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	27.0	4,701
2	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. Cancer Discovery, 2016, 6, 1118-1133.	9.4	919
3	Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. Journal of Thoracic Oncology, 2021, 16, 140-150.	1.1	95
4	Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival. Clinical Epidemiology, 2016, Volume 8, 743-750.	3.0	91
5	Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 760-770.	2.1	50
6	Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. Journal of Thoracic Oncology, 2021, 16, 259-268.	1.1	29
7	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. European Journal of Cancer, 2017, 82, 27-33.	2.8	25
8	Radiation-Induced Esophagitis is Mitigated by Soy Isoflavones. Frontiers in Oncology, 2015, 5, 238.	2.8	18
9	Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors. Translational Oncology, 2014, 7, 400-409.	3.7	15
10	Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. , 2021, 9, e001882.		12
11	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non–Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clinical Lung Cancer, 2022, 23, 21-33.	2.6	12
12	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. Lung Cancer, 2021, 155, 53-60.	2.0	8
13	Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. Journal of Biological Chemistry, 2022, 298, 101556.	3.4	4
14	Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer. Targeted Oncology, 2022, 17, 187-192.	3.6	3
15	Abstract 442: Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189. , 2021, , .		2
16	Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation. Cancer Research, 2022, 82, CT504-CT504.	0.9	2
17	New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2014, 5, 35.	2.7	0